nach oben

PharmacoEconomics

Erschienen in:

01.11.2016 | Editorial

From Good to Better: New Dutch Guidelines for Economic Evaluations in Healthcare

verfasst von: Matthijs Versteegh, Saskia Knies, Werner Brouwer

Erschienen in: PharmacoEconomics | Ausgabe 11/2016

Einloggen, um Zugang zu erhalten

Excerpt

Many countries have national guidelines for performing economic evaluations in healthcare.¹ These guidelines should ensure the comparability and quality of such evaluations, which should facilitate making well informed policy decisions regarding reimbursement of interventions. Given the developments in both the methodology and policy context of economic evaluation of healthcare interventions, these guidelines require periodical revision. Recently, the Dutch National Health Care Institute issued new guidance for economic evaluations in healthcare [1]. The new guidelines update and replace three separately published previous guidelines: those for pharmacoeconomic evaluation (latest version 2006), outcomes research (latest version 2008) as well as the Dutch costing manual (latest version 2010). In this editorial, we highlight the distinguishing features of the new Dutch guidelines. Moreover, we highlight which developments, in our opinion, are desirable in coming updates, but are still in development or controversial. …

For an overview of guidelines around the world visit http://www.ispor.org/PEguidelines/index.asp.

Questionnaires for measuring and valuing productivity costs and informal care can be found here: http://www.imta.nl/questionnaires.

The tool can also be found here: http://www.imta.nl/paid.

Nederland Zorginstituut. Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg. Diemen: Zorginstituut Nederland; 2015.

Krol M, Brouwer W. How to estimate productivity costs in economic evaluations. Pharmacoeconomics. 2014;32(4):335–44.CrossRefPubMed

Krol M, Brouwer W. Unpaid work in health economic evaluations. Soc Sci Med. 2015;144:127–37.CrossRefPubMed

Koopmanschap MA, van Ineveld BM. Towards a new approach for estimating indirect costs of disease. Soc Sci Med. 1992;34(9):1005–10.CrossRefPubMed

Koopmanschap MA, Rutten FF. Indirect costs in economic studies. Pharmacoeconomics. 1993;4(6):446–54.CrossRefPubMed

Koopmanschap MA, Rutten FFH, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ. 1995;14(2):171–89.CrossRefPubMed

Bouwmans C, Krol M, Severens H, Koopmanschap M, Brouwer W, Hakkaart-van Roijen L. The iMTA productivity cost questionnaire: a standardized instrument for measuring and valuing health-related productivity losses. Value in Health. 2015;18(6):753–8.CrossRefPubMed

Hoefman RJ, van Exel J, Brouwer W. How to include informal care in economic evaluations. Pharmacoeconomics. 2013;31(12):1105–19.CrossRefPubMed

Versteegh MM, Vermeulen KM, Evers SM, de Wit GA, Prenger R, Stolk EA. Dutch tariff for the five-level version of EQ-5D. Value Health. 2016;19(4):343–52.CrossRef

10.

Claxton K, Paulden M, Gravelle H, Brouwer W, Culyer AJ. Discounting and decision making in the economic evaluation of health-care technologies. Health Econ. 2011;20(1):2–15.CrossRefPubMed

11.

Brouwer WB, Niessen LW, Postma MJ, Rutten FF. Need for differential discounting of costs and health effects in cost effectiveness analyses. BMJ. 2005;331(7514):446–8.CrossRefPubMedPubMedCentral

12.

Ramos IC, Rutten-van Mölken MP, Al MJ. The role of value-of-information analysis in a health care research priority setting a theoretical case study. Med Decis Making. 2012;33(4):472–89.CrossRef

13.

Al M, Bindels J, Corro Ramos I, Feenstra T, Grutters J, Joore M, et al. Onzekerheid en Value of Information (VOI). Report. Diemen: Zorginstituut Nederland; 2015.

14.

Morton A, Adler A, Briggs A, Brouwer WBF, Claxton K, Fischer A, et al. Unrelated future costs and unrelated future benefits: reflections on NICE guide to the methods of technology appraisal. Health Econ. 2016;25(8):933–8.CrossRefPubMed

15.

Rappange DR, van Baal PH, van Exel N, Job A, Feenstra TL, Rutten FF, Brouwer WB. Unrelated medical costs in Life-Years gained. Pharmacoeconomics. 2008;26(10):815–30.CrossRefPubMed

16.

Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ. 1997;16(1):33–64.CrossRefPubMed

17.

van Baal P, Meltzer D, Brouwer W. Future costs, fixed healthcare budgets, and the decision rules of cost-effectiveness analysis. Health Econ. 2016;25(2):237–48.CrossRefPubMed

18.

van Baal PH, Wong A, Slobbe LC, Polder JJ, Brouwer WB, de Wit GA. Standardizing the inclusion of indirect medical costs in economic evaluations. Pharmacoeconomics. 2011;29(3):175–87.CrossRefPubMed

19.

Coast J, Flynn TN, Natarajan L, Sproston K, Lewis J, Louviere JJ, et al. Valuing the ICECAP capability index for older people. Soc Sci Med. 2008;67(5):874–82.CrossRefPubMed

20.

Lorgelly PK. Choice of outcome measure in an economic evaluation: a potential role for the capability approach. Pharmacoeconomics. 2015;33(8):849–55.CrossRefPubMed

21.

Nyman JA. Should the consumption of survivors be included as a cost in cost–utility analysis? Health Econ. 2004;13(5):417–27.CrossRefPubMed

22.

Gandjour A. Consumption costs and earnings during added years of life-a reply to Nyman. Health Econ. 2006;15(3):315–7.CrossRefPubMed

23.

Versteegh MM, Brouwer WBF. Patient and general public preferences for health states: a call to reconsider current guidelines. Soc Sci Med. 2016;165:66–74.CrossRefPubMed

24.

Brouwer WB, Van Exel N, Baltussen RM, Rutten FF. A dollar is a dollar is a dollar—or is it? Value Health. 2006;9(5):341–7.CrossRefPubMed

Titel: From Good to Better: New Dutch Guidelines for Economic Evaluations in Healthcare
verfasst von: Matthijs Versteegh
Saskia Knies
Werner Brouwer
Publikationsdatum: 01.11.2016
Verlag: Springer International Publishing
Erschienen in: PharmacoEconomics / Ausgabe 11/2016
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI: https://doi.org/10.1007/s40273-016-0431-y

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2016

Economic and Humanistic Burden of Osteoarthritis: A Systematic Review of Large Sample Studies

Cost Effectiveness of Characterised Chondrocyte Implantation for Treatment of Cartilage Defects of the Knee in the UK

Discretely Integrated Condition Event Simulation for Pharmacoeconomics

Estimating Marginal Healthcare Costs Using Genetic Variants as Instrumental Variables: Mendelian Randomization in Economic Evaluation

Response to Letter to the Editor Regarding Discretely Integrated Condition Event Simulation for Pharmacoeconomics

Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience